Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma
نویسندگان
چکیده
Abstract Pancreatic ductal adenocarcinoma (PDAC), characterized by dense desmoplastic stroma laid down pancreatic stellate cells (PSC), has no reliable diagnostic biomarkers for timely detection. A multi-center cohort of PDAC patients and controls (chronic pancreatitis, intra-ductal papillary neoplasms, gallstones otherwise healthy) donated serum in an ethically approved manner. Serum PTX3 above 4.34 ng/mL a higher sensitivity (86%, 95% confidence interval (CI): 65–97%) specificity CI: 79–91%), positive predictive value (97%) likelihood ratio (6.05), is superior when compared to CA19-9 CEA detection PDAC. In vitro ex vivo analyses PTX3, human samples, PSCs, cell lines transgenic mouse model PDAC, suggest that originates from stromal cells, mainly PSC. activated PSC, secretion could be downregulated rendering PSC quiescent using all-trans-retinoic acid (ATRA). organizes hyaluronan conjunction with tumor necrosis factor-stimulated gene 6 (TSG-6) facilitates cancer invasion. SCALOP clinical trial (ISRCTN96169987) testing chemo-radiotherapy without targeting, had prognostic or role. However, STARPAC (NCT03307148), modulation ATRA even at first dose accompanied response who later go on demonstrate disease control but not those whom the progresses. putative stromally-derived biomarker which warrants further prospective, larger, cohorts within trials targeting stroma.
منابع مشابه
Pentraxin-3 is a novel biomarker of lung carcinoma.
PURPOSE Our objective was to validate the performance of three new candidate lung cancer biomarkers, pentraxin-3 (PTX3), human kallikrein 11 (KLK11), and progranulin. EXPERIMENTAL DESIGN We analyzed by commercial ELISA, and with a blinded protocol, 422 samples from 203 patients with lung carcinoma, 180 individuals with high risk for lung cancer (heavy smokers), and 43 individuals with cancers...
متن کاملPancreatic ductal adenocarcinoma staging
In addition to clinical history and evaluations, the results of laboratory tests and imaging studies help clinicians in determining treatment strategies. Imaging plays a central role in the management of oncology patients including the initial diagnosis, staging, and follow-up to assess treatment response. Historically, radiologists have relied on free-style dictations to convey the results of ...
متن کاملPancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas. PDAC is an aggressive and difficult malignancy to treat. Complete surgical removal of the tumor remains the only chance for cure, however 80-90% of patients have disease that is surgically incurable at the time of clinical presentation (15). Despite our advancing knowledge of the tumor biology of PDAC, improv...
متن کاملPAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
PURPOSE The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis. In order to assess its role in early pancreatic cancer development, we examined the expression of the PAM4-reactive MUC1 in the noninvasive precursor lesions, pancreatic intraepithelial neoplasia (PanIN) and intraductal papilla...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: npj precision oncology
سال: 2021
ISSN: ['2397-768X']
DOI: https://doi.org/10.1038/s41698-021-00192-1